Pharmaceutical companies today face extreme pressures undermining the productivity and success rate in drug discovery and development. A steady decline in drug discovery success rates coupled with complex clinical research design and recruitment delays are key factors driving a decline in overall R&D productivity.

Our focus is to change the way potential new treatments are discovered and identified, speeding up the early phase preclinical process. The results are a more robust pipeline, higher success rates moving into clinical research and years saved in overall discovery and development.

Aria Pharmaceuticals has enjoyed partnering with like-minded pharmaceutical companies to help advance our pipeline with the spirit that collaboration can bring innovative treatments to patients even faster. We focus on first-in-class small molecules and believe in R&D excellence based on sound science, offering NCE partnerships with dramatically higher success rates at in vivo milestones compared to the traditional R&D process.


We are committed to and actively seeking partnerships for the further development and commercialization of our assets and evaluating potential opportunities to help expand our growing pipeline.

For partnership opportunities, contact Aria Pharmaceuticals at:

current partners